-
Veterinary and Comparative Oncology Dec 2010An L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) was evaluated in 66 dogs with stages III-V lymphoma. Results were compared with a... (Clinical Trial)
Clinical Trial
An L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) was evaluated in 66 dogs with stages III-V lymphoma. Results were compared with a historical group of 71 dogs treated with an L-CHOP protocol. Complete remission (CR) rates (85 and 80%, respectively) did not differ significantly between protocols (P = 0.48). First CR duration for dogs treated with L-CHOP-CCNU-MOPP was significantly longer: median, 317 days; 2-year CR rate, 35% versus median, 298 days; 2-year CR rate, 13%, P = 0.05). For the L-CHOP-CCNU-MOPP protocol, dogs in substage-b had a 4.3 times greater hazard of having a relapse than dogs in substage-a (P = 0.002). Frequency of adverse chemotherapy-associated gastrointestinal effects did not differ between protocols (P = 0.77). Neutropenia (primarily after CCNU) occurred more frequently in dogs treated with L-CHOP-CCNU-MOPP (P < 0.001). In summary, the L-CHOP-CCNU-MOPP protocol showed an improved duration of first CR as compared with an L-CHOP protocol, but the relevance of this finding might be subject to clinical judgement.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Cyclophosphamide; Dog Diseases; Dogs; Doxorubicin; Female; Lomustine; Lymphoma; Male; Mechlorethamine; Prednisone; Procarbazine; Retrospective Studies; Risk Factors; Vincristine
PubMed: 21062406
DOI: 10.1111/j.1476-5829.2010.00224.x -
Journal of Clinical Oncology : Official... Jan 1987
Comparative Study
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Mechlorethamine; Prednisone; Procarbazine; Vinblastine; Vincristine
PubMed: 2433410
DOI: 10.1200/JCO.1987.5.1.7 -
Journal of Clinical Oncology : Official... Sep 1986
Topics: Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Vincristine
PubMed: 3755754
DOI: 10.1200/JCO.1986.4.9.1289 -
Journal of Clinical Oncology : Official... Dec 1989
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Vincristine
PubMed: 2585017
DOI: 10.1200/JCO.1989.7.12.1766 -
Hematological Oncology 1993
Comparative Study
Topics: Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Mechlorethamine; Practice Patterns, Physicians'; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Vincristine
PubMed: 8406376
DOI: 10.1002/hon.2900110203 -
Journal of Clinical Oncology : Official... Feb 1987
Topics: Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Vincristine
PubMed: 3806177
DOI: 10.1200/JCO.1987.5.2.320 -
Hematology/oncology Clinics of North... Jun 1989MOPP chemotherapy was the significant breakthrough that improved the outlook for patients with advanced Hodgkin's disease. Results with alternating potentially... (Clinical Trial)
Clinical Trial Randomized Controlled Trial Review
MOPP chemotherapy was the significant breakthrough that improved the outlook for patients with advanced Hodgkin's disease. Results with alternating potentially non-cross-resistant drug combinations, including MOPP/ABVD, CAD/MOPP/ABV, and MOPP/ABV, are similar and seem to be slightly superior to those with MOPP alone. Limited adjuvant RT does not seem to add appreciably to the morbidity of chemotherapy, although its role in improving on results with chemotherapy alone has not been well studied in prospective, randomized, controlled clinical trials. There are two major challenges for the future. The first is to improve the outcome for advanced Hodgkin's disease patients, perhaps with more intensive chemotherapy and RT with use of cytokines such as the colony-stimulating factors or interleukin-1 or with rescue employing autologous bone marrow transplantation or both. The second challenge is to reduce the morbidity but not the effectiveness of treatment for advanced Hodgkin's disease patients without adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia; Lomustine; Lymphoma; Male; Mechlorethamine; Melphalan; Middle Aged; Neoplasms, Multiple Primary; Prednisone; Procarbazine; Remission Induction; Vinblastine; Vincristine; Vindesine
PubMed: 2473061
DOI: No ID Found -
International Journal of Radiation... May 2015
Topics: Antineoplastic Combined Chemotherapy Protocols; Congresses as Topic; History, 19th Century; History, 20th Century; Hodgkin Disease; Humans; Lymphoma; Mechlorethamine; New York City; Paris; Prednisone; Procarbazine; Vincristine
PubMed: 25863746
DOI: 10.1016/j.ijrobp.2015.03.009 -
Blood Feb 1999
Review
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Cardiomyopathies; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Dacarbazine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infections; Laparotomy; Lung Diseases, Interstitial; Lymphography; Mechlorethamine; Middle Aged; Neoplasm Staging; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prednisone; Procarbazine; Prognosis; Radiation Injuries; Radiotherapy; Remission Induction; Salvage Therapy; Vinblastine; Vincristine
PubMed: 9920825
DOI: No ID Found -
Journal of Feline Medicine and Surgery Apr 2020The aims of this study were to evaluate the safety of mustargen, vincristine, procarbazine and prednisone (MOPP) chemotherapy in the treatment of relapsed or refractory...
OBJECTIVES
The aims of this study were to evaluate the safety of mustargen, vincristine, procarbazine and prednisone (MOPP) chemotherapy in the treatment of relapsed or refractory feline lymphoma, and to determine the overall response rate and median remission time with this protocol.
METHODS
The medical records of 38 cats with relapsed or refractory lymphoma treated with MOPP chemotherapy at three institutions (University of Pennsylvania, the Animal Medical Center, and VCA Western Veterinary Specialist and Emergency Centre) were examined. Information evaluated included patient signalment, feline immunodeficiency virus/feline leukemia virus status, anatomic location(s) of lymphoma, prior protocols (type and number), MOPP doses, MOPP response, remission duration, hematologic and biochemical parameters, and owner-reported adverse effects.
RESULTS
Overall, 70.3% of cats responded to MOPP chemotherapy. Among the responders, the median remission duration was 166 days. The most common adverse effects were neutropenia and gastrointestinal upset, which were reported in 18.4% of cats. In 55.3% of cats, no adverse effects were reported. In total, 30.8% of responders continued to respond 6 months following the initiation of MOPP, and 15.4% maintained a response 1 year after starting MOPP.
CONCLUSIONS AND RELEVANCE
MOPP is a safe protocol for the treatment of relapsed or refractory feline lymphoma, with a promising overall response rate and median remission time.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Lymphoma; Mechlorethamine; Prednisone; Procarbazine; Treatment Outcome; Vincristine
PubMed: 30994392
DOI: 10.1177/1098612X19841916